Glenmark Life Sciences Ltd
NSE:GLS
Intrinsic Value
Glenmark Life Sciences Ltd. engages in the development and manufacture of non-commoditized active pharmaceutical ingredients. [ Read More ]
The intrinsic value of one GLS stock under the Base Case scenario is 618.86 INR. Compared to the current market price of 800 INR, Glenmark Life Sciences Ltd is Overvalued by 23%.
Valuation Backtest
Glenmark Life Sciences Ltd
Run backtest to discover the historical profit from buying and selling GLS stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Glenmark Life Sciences Ltd
| Current Assets | 20.8B |
| Cash & Short-Term Investments | 4.4B |
| Receivables | 8.1B |
| Other Current Assets | 8.3B |
| Non-Current Assets | 8.8B |
| Long-Term Investments | 770k |
| PP&E | 8.4B |
| Intangibles | 172.4m |
| Other Non-Current Assets | 151.8m |
| Current Liabilities | 5B |
| Accounts Payable | 3.9B |
| Accrued Liabilities | 211.8m |
| Other Current Liabilities | 926.2m |
| Non-Current Liabilities | 622.4m |
| Long-Term Debt | 159.9m |
| Other Non-Current Liabilities | 462.4m |
Earnings Waterfall
Glenmark Life Sciences Ltd
|
Revenue
|
23.7B
INR
|
|
Cost of Revenue
|
-10.4B
INR
|
|
Gross Profit
|
13.2B
INR
|
|
Operating Expenses
|
-6.2B
INR
|
|
Operating Income
|
7B
INR
|
|
Other Expenses
|
-1.8B
INR
|
|
Net Income
|
5.2B
INR
|
Free Cash Flow Analysis
Glenmark Life Sciences Ltd
What is Free Cash Flow?
GLS Profitability Score
Profitability Due Diligence
Glenmark Life Sciences Ltd's profitability score is 64/100. The higher the profitability score, the more profitable the company is.
Score
Glenmark Life Sciences Ltd's profitability score is 64/100. The higher the profitability score, the more profitable the company is.
GLS Solvency Score
Solvency Due Diligence
Glenmark Life Sciences Ltd's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Score
Glenmark Life Sciences Ltd's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
GLS Price Targets Summary
Glenmark Life Sciences Ltd
According to Wall Street analysts, the average 1-year price target for GLS is 892.16 INR with a low forecast of 772.65 INR and a high forecast of 987 INR.
Shareholder Return
GLS Price
Glenmark Life Sciences Ltd
| Average Annual Return | -23.22% |
| Standard Deviation of Annual Returns | 11.24% |
| Max Drawdown | -49% |
| Market Capitalization | 98B INR |
| Shares Outstanding | 122 527 000 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Glenmark Life Sciences Ltd. engages in the development and manufacture of non-commoditized active pharmaceutical ingredients. The company is headquartered in Solapur, Maharashtra. The company went IPO on 2021-08-06. The Company’s product portfolio comprises of various therapeutic segments, which include cardiovascular (CVS) disease, central nervous system (CNS) disorders, diabetes, gastrointestinal health, oncology, pain management and anti-infectives. Its products include Adapalene, Alogliptin Benzoate, Amiodarone HCl, Esomeprazole Sodium, Eszopiclone, Etoricoxib, Omeprazole, Oxcarbazepine, Zolpidem Tartrate, Zonisamide and Voriconazole. The Company’s products also include Vildagliptin, Aprepitant, Bosentan, Cilostazol, Deferasirox, Fluconazole, Ivacaftor, Pirfenidone, Riluzole, Sucralfate, Ticagrelor, Telmisartan and Umifenovir. The Company’s research and development facilities are located at Mahape, Ankleshwar and Dahej in India and manufacturing facilities are located at Ankleshwar, Dahej, Mohol and Kurkumbh.
Contact
IPO
Employees
Officers
The intrinsic value of one GLS stock under the Base Case scenario is 618.86 INR.
Compared to the current market price of 800 INR, Glenmark Life Sciences Ltd is Overvalued by 23%.
You don't have any saved screeners yet
